New studies in vitro antibacterial evaluation and cell viability in PMMA-G-PEG 4000 derivatives with encapsulated Erythromycin.

Abstract

Synthetic polymers have been extensively studied in several areas of knowledge, one of which is the pharmaceutical. The drug when encapsultated into the PMMA-g-PEG 4000 matrix can produce fewer side effects. The most frequent side effects of erythromycin are gastrointestinal and are dose related. Nausea, vomiting and diarrhea occur in low frequency with the usual oral doses. The drug used in this study was Erythromycin, an antimicrobial that acts directly on bacterial protein synthesis. Erythromycin was encapsulated into PMMA-g-PEG 4000 derivatives. All copolymers afther encapsultaions were characterized and identified by atomic force microscopy (AFM). In vitro assays of release, antimicrobial activity and cytotoxicity were performed for the copolymers obtained. The copolymers PMMA-g-PEG 4000 HAL and PMMA-g-PEG 4000 ACET showed drug controlled release profiles. All PMMA-g-PEG 4000 derivatives showed antibacterial activity against Staphylococcus aureus and did not show a cytotoxic effect on human fibroblasts.